Search

MediciNova Inc

Slēgts

SektorsVeselības aprūpe

3.27 -4.11

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.25

Max

3.51

Galvenie mērījumi

By Trading Economics

Ienākumi

-2.3B

-2.3B

Pārdošana

271K

458K

EPS

-0.05

Peļņas marža

-504,786.678

Darbinieki

6

EBITDA

5.1K

-2.5M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+120.88% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 10. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

27M

92M

Iepriekšējā atvēršanas cena

7.38

Iepriekšējā slēgšanas cena

3.27

Ziņu noskaņojums

By Acuity

64%

36%

287 / 339 Rangs Healthcare

MediciNova Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. sept. 23:36 UTC

MediciNova Inc is trading higher in after-market hours, maintaining a significant advance from Friday's close and remaining well above its 20-day moving average.

2026. g. 17. sept. 23:06 UTC

MediciNova Inc is trading roughly flat in after-market hours, maintaining little change since Thursday's close after a month of strong gains.

2026. g. 16. sept. 22:51 UTC

MediciNova Inc's shares rose significantly in after-market trading, showing strong upward movement and notable volatility since the market closed.

2026. g. 15. sept. 20:01 UTC

Shares of MediciNova Inc. are higher today amid notable volatility. The stock rebounded after an early dip, reflecting broader market sentiment concerns.

2026. g. 14. sept. 20:03 UTC

MediciNova Inc shares are higher today, continuing a notable advance since Friday. The stock remains near the upper end of its one-month trading range.

2026. g. 11. sept. 20:08 UTC

MediciNova Inc shares are higher today, reflecting strong market momentum since Thursday's close, maintaining a position above the 20-day moving average.

2026. g. 10. sept. 20:03 UTC

MediciNova Inc. shares are lower during Thursday's session, following an early peak. The decline contrasts with four consecutive higher sessions amid broader market volatility.

2026. g. 9. sept. 20:01 UTC

MediciNova Inc shares are higher today, continuing an upward trend since Tuesday's close. The stock remains well above recent averages.

2026. g. 8. sept. 23:01 UTC

MediciNova Inc shares are higher in after-market trading, marking five consecutive sessions of gains. No specific news was identified to explain this movement.

2026. g. 4. sept. 20:07 UTC

MediciNova Inc. shares are higher today, maintaining a positive trend since Thursday's close and remaining above the 20-day moving average.

2026. g. 3. sept. 20:02 UTC

MediciNova Inc is trading higher, reflecting strong buying interest since Wednesday's close. The stock remains near the upper end of its one-month trading range.

2026. g. 28. aug. 20:07 UTC

Shares of MediciNova Inc. are higher today, reflecting positive momentum. The stock is trading well above its 20-day moving average.

2026. g. 27. aug. 20:03 UTC

MediciNova Inc. shares are lower today, continuing a downward trend since Wednesday's close, despite remaining above the 20-day moving average.

2026. g. 26. aug. 19:08 UTC

MediciNova Inc shares are lower today, reflecting significant volatility after three consecutive sessions of gains. No specific news was identified to explain the decline.

2026. g. 25. aug. 19:36 UTC

MediciNova Inc. shares are higher today, supported by a strong performance backdrop and broader market sentiment from lower crude oil prices and declining Treasury yields.

2026. g. 24. aug. 20:02 UTC

MediciNova Inc shares are higher today, continuing a strong upward trend since Friday's close. The stock remains near the upper end of its one-month range.

2026. g. 21. aug. 19:56 UTC

MediciNova Inc's shares are higher today, continuing a positive trend. The stock is trading above its 20-day moving average amid gains in the cryptocurrency sector.

2026. g. 20. aug. 19:16 UTC

MediciNova Inc. shares are lower today, having previously declined significantly before recovering. The price remains above its 20-day moving average.

2026. g. 18. aug. 19:56 UTC

MediciNova Inc shares are higher, reflecting positive market momentum. The stock remains above its 20-day moving average and near the upper end of its one-month range.

2026. g. 17. aug. 19:56 UTC

News

MediciNova shares are higher as the company reported earnings of -$0.05 per share, surpassing estimates and generating $0.46 million in revenue.

2026. g. 13. aug. 19:26 UTC

MediciNova Inc shares are lower amid broader market pressure from rising jobless claims and stabilizing inflation indicators. The stock trades near its one-month range low.

2026. g. 12. aug. 19:56 UTC

MediciNova Inc. shares are trading roughly flat with no specific news identified, remaining near the lower end of their one-month trading range.

2026. g. 11. aug. 20:06 UTC

MediciNova Inc. shares are roughly flat, showing little movement since Monday's close and positioned near the lower end of their one-month trading range.

2026. g. 10. aug. 19:46 UTC

MediciNova Inc shares are lower today, continuing a downward trend since Friday. Broader market sentiment is affected by recent U.S. employment data.

2026. g. 7. aug. 19:46 UTC

MediciNova Inc. shares are higher today, recovering from earlier losses. The stock is trading around the middle of its one-month range.

2026. g. 6. aug. 20:13 UTC

MediciNova Inc shares are higher in after-market trading, reflecting strength since Thursday's close amid rising U.S. Treasury yields and a hawkish Fed outlook.

2026. g. 4. aug. 19:36 UTC

MediciNova Inc. shares are trading roughly flat amid broader market reactions to a decline in U.S. core factory orders and ongoing strength in AI sectors.

2026. g. 3. aug. 20:06 UTC

MediciNova Inc. shares are lower, continuing a decline since Friday's close, despite positive movements in major indices like the S&P 500 and Nasdaq 100.

2026. g. 31. jūl. 19:56 UTC

Shares of MediciNova Inc. are lower during Friday's session, following a routine decline after an early high. The stock is below its 20-day moving average.

2026. g. 30. jūl. 20:51 UTC

MediciNova Inc's shares are lower in after-market hours, reflecting a broader decline in the Biotechnology sub-sector. The asset is near its one-month trading range low.

Salīdzinājums

Cenas izmaiņa

MediciNova Inc Prognoze

Cenas mērķis

By TipRanks

120.88% augšup

Prognoze 12 mēnešiem

Vidējais 7.333 USD  120.88%

Augstākais 10 USD

Zemākais 6 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi MediciNova Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

3

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

287 / 339 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.